Herein it revealed that in contrast to this ErbB2-Herceptin line, the YS110 treatment abundantly induces nuclear localization of CD26 and in consequentially suppresses POLR2A expression, leading to inhibition of tumor cell growth. This evidence concerns the gene POLR2A and neoplasm.